A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants
Condition: Healthy Volunteers
Intervention: TAK-831 Oral Tablet; [14C]TAK-831 IV Infusion; [14C]TAK-831 Oral Suspension
Intervention description: TAK-831 tablet.; [14C]TAK-831 IV infusion.; [14C]TAK-831 oral suspension.
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 6.0
Sex: Male
Minimum age: 19 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Drug Therapy

Summary:

      The purpose of this study is to determine ABA of TAK-831 following a single microdose
      intravenous administration of 50 microgram (μg) (approximately 1 microcurie [μCi])
      [14C]TAK-831 and a single oral administration of 500 milligram (mg) TAK-831 tablets in Period
      1, and to assess the mass balance, characterize the PK of TAK-831 in plasma and urine, and
      total radioactivity concentration equivalents in plasma and whole blood following a single
      oral suspension dose of 500 mg (approximately 100 μCi) [14C]TAK-831 in Period 2.
    

Eligibility criteria:

        Inclusion Criteria:

        1. Weighs at least 45 kilogram (kg) and body mass index (BMI) greater than or equal to (>=)
        18.0 and less than (˂) 32.0 kilogram per square meter (kg/m^2) at screening.

        Exclusion Criteria:

          1. Seated blood pressure is less than 90/40 millimeter of mercury (mmHg) or greater than
             140/90 mmHg at screening.

          2. Seated heart rate is lower than 40 beats per minute (bpm) or higher than 99 bpm at
             screening.

          3. Estimated creatinine clearance <80 milliliter per minute (mL/min) at screening.

          4. Has tattoo(s) or scarring at or near the site of intravenous infusion or any other
             condition which may interfere with infusion site examination, in the opinion of the
             Investigator.

          5. Has infrequent bowel movements (less than approximately once per day) within 30 days
             prior to first dosing.

          6. Has received radiolabeled substances or has been exposed to radiation sources within
             12 months of first dosing or is likely to receive radiation exposure or radioisotopes
             within 12 months of first dosing such that participation in this study would increase
             their total exposure beyond the recommended levels considered safe (that is weighted
             annual limit recommended by the International Commission on Radiological Protection
             [ICRP] of 3000 milli roentgen equivalent man [mrem]).

          7. Has been on a diet incompatible with the on-study diet, in the opinion of the
             Investigator or designee, within the 30 days prior to the first dosing and throughout
             the study.

          8. Donation of blood or significant blood loss within 56 days prior to the first dosing.

          9. Plasma donation within 7 days prior to the first dosing.